Develops precision antibody therapeutics for patients with autoimmune diseases that selectively deplete pathogenic T cell subsets driving chronic inflammation and disease progression. Uses human pathway signatures and transcription factor‑linked membrane targets to drug functional‑state epitopes in the disease context for highly selective, potentially curative treatments.